These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21077637)

  • 1. Molecular topology analysis of the differences between drugs, clinical candidate compounds, and bioactive molecules.
    Chen H; Yang Y; Engkvist O
    J Chem Inf Model; 2010 Dec; 50(12):2141-50. PubMed ID: 21077637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive activity profiling of drugs by topological-fragment-spectra-based support vector machines.
    Kawai K; Fujishima S; Takahashi Y
    J Chem Inf Model; 2008 Jun; 48(6):1152-60. PubMed ID: 18533712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs.
    Hu Y; Bajorath J
    J Chem Inf Model; 2010 Dec; 50(12):2112-8. PubMed ID: 21070069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The properties of known drugs. 1. Molecular frameworks.
    Bemis GW; Murcko MA
    J Med Chem; 1996 Jul; 39(15):2887-93. PubMed ID: 8709122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the relationship between topology and selectivity for druglike molecules.
    Yang Y; Chen H; Nilsson I; Muresan S; Engkvist O
    J Med Chem; 2010 Nov; 53(21):7709-14. PubMed ID: 20942392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Bayes affinity fingerprints" improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept?
    Bender A; Jenkins JL; Glick M; Deng Z; Nettles JH; Davies JW
    J Chem Inf Model; 2006; 46(6):2445-56. PubMed ID: 17125186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry.
    Feher M; Schmidt JM
    J Chem Inf Comput Sci; 2003; 43(1):218-27. PubMed ID: 12546556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tools and methodologies capable of isolating and identifying a target molecule for a bioactive compound.
    Sakamoto S; Hatakeyama M; Ito T; Handa H
    Bioorg Med Chem; 2012 Mar; 20(6):1990-2001. PubMed ID: 22264760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the influence of molecular topology on ligand binding.
    Oka R; Engkvist O; Chen H
    J Mol Graph Model; 2013 Mar; 40():22-9. PubMed ID: 23353581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaffold distributions in bioactive molecules, clinical trials compounds, and drugs.
    Hu Y; Bajorath J
    ChemMedChem; 2010 Feb; 5(2):187-90. PubMed ID: 20014088
    [No Abstract]   [Full Text] [Related]  

  • 13. Bioisosteric similarity of molecules based on structural alignment and observed chemical replacements in drugs.
    Krier M; Hutter MC
    J Chem Inf Model; 2009 May; 49(5):1280-97. PubMed ID: 19402687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Core trees and consensus fragment sequences for molecular representation and similarity analysis.
    Lounkine E; Bajorath J
    J Chem Inf Model; 2008 Jun; 48(6):1161-6. PubMed ID: 18491888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
    Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
    Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical property profiles of marketed drugs, clinical candidates and bioactive compounds.
    Tyrchan C; Blomberg N; Engkvist O; Kogej T; Muresan S
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6943-7. PubMed ID: 19879759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A scoring scheme for discriminating between drugs and nondrugs.
    Sadowski J; Kubinyi H
    J Med Chem; 1998 Aug; 41(18):3325-9. PubMed ID: 9719584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular hydrogels of therapeutic agents.
    Zhao F; Ma ML; Xu B
    Chem Soc Rev; 2009 Apr; 38(4):883-91. PubMed ID: 19421568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds.
    Ertl P; Jelfs S; Mühlbacher J; Schuffenhauer A; Selzer P
    J Med Chem; 2006 Jul; 49(15):4568-73. PubMed ID: 16854061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward accurate relative energy predictions of the bioactive conformation of drugs.
    Butler KT; Luque FJ; Barril X
    J Comput Chem; 2009 Mar; 30(4):601-10. PubMed ID: 18711721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.